Revenue ₹619 Cr (-13% YoY)
0 met · 0 close · 1 missed across 1 tracked promises
View all executive profiles for Cohance Lifesciences LtdCohance Lifesciences reported FY26 revenue of ₹22.68B, down 13% YoY, with adjusted EBITDA margin of 21% (standalone 2...
0% promises delivered
Based on 1 tracked promises across 3 quarters
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Quarterly Earnings Timeline
Financial verification status, call summary, sentiment, and management-delivery signals by quarter.
Q4 FY26
15 May 2026
Revenue ₹619 Cr (-13% YoY)
Cohance Lifesciences reported FY26 revenue of ₹22.68B, down 13% YoY, with adjusted EBITDA margin of 21% (standalone 24.6%).
bearish
high
1 missed
Read full analysis →
Q3 FY26
10 Feb 2026
Revenue ₹545 Cr (-19.5% YoY)
Cohance Lifesciences reported a weak Q3 FY26 with consolidated revenue declining 19.5% YoY to ₹545 crore, impacted by destocking in two large commercial products (~₹26...
bearish
high
Scorecard starts after historical backfill
Read full analysis →
Q1 FY26
13 Aug 2025
Revenue ₹549 Cr (+13% YoY)
Cohance Life Sciences reported Q1 FY26 revenue growth of 13% YoY, with pharma CDMO growing over 30% excluding inventory destocking.
bullish
medium
Scorecard starts after historical backfill
Read full analysis →